Simona Morochnik1, Eugene Ozhinsky1, Viola Rieke2, Matthew D Bucknor1. 1. Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA. 2. Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT, USA.
Abstract
Objective: The objective of this study was to develop an alternative method of non-contrast monitoring of tissue ablation during focused ultrasound treatment. Desmoid tumors are benign but locally aggressive soft tissue tumors that arise from fibroblast cells. Magnetic resonance-guided focused ultrasound (MRgFUS) has emerged as an alternative to conventional therapies, showing promising results in reduction of tumor volume without significant side effects. The gold-standard assessment of the reduction of viable tumor volume post-treatment is non-perfused volume (NPV) and evaluation of NPV is typically performed with post-treatment gadolinium enhanced MR imaging. However, as gadolinium cannot be repeatedly administered during treatments, there is a need for alternative non-contrast monitoring of the tissue to prevent over and under treatment. Methods: Double-echo and multi-echo images were acquired before, during and after the MRgFUS treatment. T2 maps were generated with an exponential fit and T2 maps were compared to post-treatment post-contrast images. Results: In all five MRgFUS treatment sessions, T2 mapping showed excellent qualitative agreement with the post-contrast NPV.Conclusions: T2 mapping may be used to visualize the extent of ablation with focused ultrasound and can be used as a predictor of NPV prior to the administration of contrast during the post-treatment assessment.
Objective: The objective of this study was to develop an alternative method of non-contrast monitoring of tissue ablation during focused ultrasound treatment. Desmoid tumors are benign but locally aggressive soft tissue tumors that arise from fibroblast cells. Magnetic resonance-guided focused ultrasound (MRgFUS) has emerged as an alternative to conventional therapies, showing promising results in reduction of tumor volume without significant side effects. The gold-standard assessment of the reduction of viable tumor volume post-treatment is non-perfused volume (NPV) and evaluation of NPV is typically performed with post-treatment gadolinium enhanced MR imaging. However, as gadolinium cannot be repeatedly administered during treatments, there is a need for alternative non-contrast monitoring of the tissue to prevent over and under treatment. Methods: Double-echo and multi-echo images were acquired before, during and after the MRgFUS treatment. T2 maps were generated with an exponential fit and T2 maps were compared to post-treatment post-contrast images. Results: In all five MRgFUS treatment sessions, T2 mapping showed excellent qualitative agreement with the post-contrast NPV.Conclusions: T2 mapping may be used to visualize the extent of ablation with focused ultrasound and can be used as a predictor of NPV prior to the administration of contrast during the post-treatment assessment.
Authors: Peter D Peng; Omar Hyder; Michael N Mavros; Ryan Turley; Ryan Groeschl; Amin Firoozmand; Michael Lidsky; Joseph M Herman; Michael Choti; Nita Ahuja; Robert Anders; Daniel G Blazer; T Clark Gamblin; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2012-09-13 Impact factor: 5.344
Authors: Paul Baron; Mario Ries; Roel Deckers; Martijn de Greef; Jukka Tanttu; Max Köhler; Max A Viergever; Chrit T W Moonen; Lambertus W Bartels Journal: Magn Reson Med Date: 2013-11-20 Impact factor: 4.668
Authors: R Catane; A Beck; Y Inbar; T Rabin; N Shabshin; S Hengst; R M Pfeffer; A Hanannel; O Dogadkin; B Liberman; D Kopelman Journal: Ann Oncol Date: 2006-10-09 Impact factor: 32.976
Authors: Joost W Wijlemans; Roel Deckers; Maurice A A J van den Bosch; Beatrijs A Seinstra; Marijn van Stralen; Paul J van Diest; Chrit T W Moonen; Lambertus W Bartels Journal: Invest Radiol Date: 2013-06 Impact factor: 6.016